Longevity & AgingGLP-1 and SGLT-2 Drugs Linked to Shifting Autoimmune Disease Risks in Large Study
Researchers analyzed hundreds of thousands of patient records to compare autoimmune disease risks among three classes of newer diabetes medications: GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors. The study, published in ACR Open Rheumatology, found that DPP-4 inhibitors carried notably higher risks for bullous pemphigoid and dermatomyositis compared to both other drug classes, while GLP-1 drugs were linked to higher rates of psoriasis, psoriatic arthritis, and autoimmune thyroiditis than DPP-4 inhibitors. GLP-1 and SGLT-2 drugs showed no significant differences across all 19 autoimmune conditions examined. Researchers caution these are preliminary signals, not confirmed causal relationships, and call for deeper mechanistic studies.
